Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

d for the full year 2007.

General and administrative expenses in the fourth quarter of 2007 decreased to $1.8 million from $3.0 million in the year ago period resulting mainly from cost controls and less outsourced services. General and administrative expenses for the full year 2007 decreased to $6.1 million from $7.7 million for the full year 2006. This decrease was principally a result of legal and consulting expenses capitalized upon the completion of the IPO in 2007 compared to costs related to the unsuccessful IPO attempt in 2006 that were expensed.

On December 31, 2007, ImaRx had $12.9 million in cash, cash equivalents and investments, excluding $0.4 million in restricted cash, compared to $4.3 million in cash, cash equivalents and investments on December 31, 2006. The increase in the cash balance was primarily related to the $9.0 million sale of Abbokinase, net of discounts and fees, to two primary wholesale distributors and the $12.4 million in net proceeds received from the common stock offering in connection with the Company's July 2007 IPO. Assuming the tentative agreement with Abbott regarding the remaining balance of the $15.0 million note is executed and a strategic financing alternative for SonoLysis is achieved, the Company believes it will have sufficient cash resources for at least the next 12 months.

Additionally, in connection with the filing of its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2008, Ernst & Young LLP, the Company's independent registered public accounting firm, noted that the Company has recurring losses, which has resulted in a significant accumulated deficit at December 31, 2007. In addition, the Company has a significant note payable balance due on March 31, 2008. These conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern.

Conference Call and Webcast Information

Management will host a conferen
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 Research and Markets has ... Market 2014-2018" report to their offering. ... synthetic biology covers the designing and engineering of completely ... the redesigning of natural biological systems that provide improved ... form of extreme genetic engineering because it not only ...
(Date:7/28/2014)... , July 28, 2014 ... report  "Microbial Identification Market by Products (Consumables, Instruments, Services), ... Beverages), End User (Detection, Characterization) - Global ... Microbial Identification Market is estimated at $896.5 ... reach $1,194.1 Million by 2019, growing at ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Immunomic Therapeutics, ... researchers to further develop potential treatments for glioblastoma multiforme ... in combination with their patented vaccine platform, LAMP-vax. ... University, are based on the work of John H. ... at The Preston Robert Tisch Brain Tumor Center at ...
(Date:7/28/2014)... Appistry, Inc. , a leading provider ... of genomics to next-generation medicine, announced today its judging ... , Two Appistry staff will be joined by ... Genome Resources, and Mr. Neil Miller, director of informatics ... Rounding out the panel are Appistry’s Dr. Richard Mazzarella, ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2
... (NYSE: SGP ) will provide a live ... Ph.D., executive vice president and president, Schering-Plough Research Institute, ... San Francisco on Monday, Jan. 12, at approximately 3:30 ... to talk about the company,s R&D pipeline and select ...
... 9 Endo Pharmaceuticals (Nasdaq: ENDP ) announced ... Endo, will present a corporate update at the J.P. Morgan ... 10:30 a.m. Pacific Time. The conference will be held ... live audio Webcast of the presentation may be accessed on ...
... Ireland, January 9 Azur Pharma Limited ... exclusive U.S. marketing rights,for Niravam(R) (alprazolam orally ... (baclofen,orally disintegrating tablets) and Fluxid(TM) (famotidine orally,disintegrating ... were not,disclosed. , ...
Cached Biology Technology:Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB 2
(Date:7/25/2014)... Before the colonial era, 100,000s of people lived on ... cultures manipulated fire to control the availability of plants ... tribes continue to use fire to maintain desired habitat ... the U.S. Forest Service,s Pacific Southwest Station, will lead ... National Wildfire Refuge during the Ecological Society of America,s ...
(Date:7/25/2014)... study published online in the International Journal of ... to preventing cervical cancer based on findings showing successful ... of a discrete population of cells in the cervix. ... looked at squamocolumnar junction cells, or SCJ cells. These ... implicated as the origins of cervical cancer. A research ...
(Date:7/25/2014)... the way for the development of new lines of barley ... production is second only to wheat with 7-8 million tonnes ... diseases of barley. , Senior Research Scientist Dr Alan Little ... the cell walls of barley plants that block the penetration ... the ARC Centre of Excellence in Plant Cell Walls in ...
Breaking Biology News(10 mins):Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3Clearing cells to prevent cervical cancer 2New hope for powdery mildew resistant barley 2
... new role for a key cancer protein, a finding that ... variety of tumors. Many cancers are driven in part ... to escape growth controls and proliferate abnormally. In the new ... , researchers discovered that cyclin D1 also helps cancer cells ...
... by the Biotechnology and Biological Sciences Research Council (BBSRC)-led ... an enzyme in bacteria which could be used to ... in the 14 June Issue of the American Chemical ... out by teams at the Universities of Warwick and ...
... (June 9, 2011) − Mice born to mothers who are ... to develop intestinal tumors, report scientists at the Jean Mayer ... Tufts University. Previous research in humans and mice ... the prevention of colorectal cancer. Using a mouse model of ...
Cached Biology News:Cancer protein discovery may aid radiation therapy 2Cancer protein discovery may aid radiation therapy 3First wood-digesting enzyme found in bacteria could boost biofuel production 2B vitamins in mother's diet reduce colorectal cancer risk in offspring 2
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
... standard for whole-blood clinical diagnostic work in ... less, this analyzer makes precise glucose measurements ... precise lactate measurements of whole blood, plasma, ... option allows you to have glucose results ...
... The first high-density serum biomarker chip to ... proteins. An antibody chip containing 120 human ... that enables biomarker discovery scientists to study ... benefits of therapy and the likelihood of ...
... description: The Costar strip ejector is a ... of Costar strips from their holder. Linkage: ... number, created to easily match Cornings product ... order under the old Sigma-Aldrich number (Z71,314-7) ...
Biology Products: